Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6336422 | 0.76 | TP53 (0.38) | L3MBTL1KDM4E | |
| SCHEMBL24045678 | 0.72 | ALDH1A1 (0.42) | KDM4E | |
| SCHEMBL6079108 | 0.72 | EPHX2 (0.37) | — | |
| SCHEMBL6078026 | 0.69 | CHRM1 (0.33) | — | |
| SCHEMBL6079159 | 0.69 | NOS3 (0.30) | — | |
| SCHEMBL6327598 | 0.68 | CHRNB2 (0.34) | KDM4E | |
| SCHEMBL25179800 | 0.65 | TAAR1 (0.46) | KDM4E | |
| SCHEMBL4971203 | 0.65 | NPSR1 (0.33) | — | |
| SCHEMBL4424354 | 0.63 | EPHX1 (0.40) | — | |
| SCHEMBL25184407 | 0.61 | TAAR1 (0.42) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7119109-B2 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2006-10-10 | — | — | US | disclosed |
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | ASTRAZENECA AB (SE) | 2004-11-04 | — | — | US | disclosed |
| EP-1421067-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003011831-A1 | HETEROARYLHETEROALKYLAMINE DERIVATIVES AND THEIR USE AS INHIBITORS OF NITRIC OXIDE SYNTHASE | ASTRAZENECA AB (SE) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220234-A1 | Heteroarylheteroalkylamine derivatives and their use as inhibitors of nitric oxide synthase | NOS3, NOS2, NOS1 | L3MBTL1 1493/4885KDM4E 1533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.